How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab-Reference-Cited by-同舟云学术

How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab

Published:2015-07 Issue:4 Volume:11 Page:313-318
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Dusetzina Stacie B.¹,Ellis Shellie¹,Freedman Rachel A.¹,Conti Rena M.¹,Winn Aaron N.¹,Chambers James D.¹,Alexander G. Caleb¹,Huskamp Haiden A.¹,Keating Nancy L.¹

Affiliation:

1. UNC Eshelman School of Pharmacy; University of North Carolina at Chapel Hill, Gillings School of Global Public Health; UNC Lineberger Comprehensive Cancer Center; Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC; University of Kansas School of Medicine, Kansas City, KS; Dana-Farber Cancer Institute; Tufts Medical Center Institute for Clinical Research and Health Policy Studies; Harvard Medical School; Brigham and Women's Hospital, Boston, MA; University of Chicago, Chicago, IL; Center...

Abstract

Although insurers varied in terms of public statements regarding coverage intentions, bevacizumab use declined similarly among all payers, suggesting that provider decision making, rather than payer-specific coverage policies, drove reductions.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology(nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.2015.004218

Reference29 articles.

1. FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer

2. FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma

3. FDA Drug Approval Summary: Bevacizumab (Avastin®) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell Lung Cancer

4. FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

5. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two views of cancer medicines: Imagery versus evidence;Health Marketing Quarterly;2022-01-07

2. The Perils of Increasing Medicaid Rebates for Drugs With Accelerated Approval;JAMA Health Forum;2021-10-08

3. A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises;JNCI: Journal of the National Cancer Institute;2019-10-25

4. Over-treatment in metastatic breast cancer;The Breast;2017-02